DKCM
RVMD icon

Davidson Kempner Capital Management’s Revolution Medicines RVMD Stock Holding History

Davidson Kempner Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,075
Closed -$2.63M – 281
2026
Q1 		$2.63M Buy
+27,075
New +$2.73M 0.03% 167
2020
Q2 		– Sell
-14,000
Closed -$305K – 205
2020
Q1 		$305K Buy
+14,000
New +$388K 0.01% 146

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Davidson Kempner Capital Management's RVMD Position: Q2 2026 in Review

Davidson Kempner Capital Management sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 27,075 shares — an estimated $2.63M sold.

Davidson Kempner Capital Management first reported a position in RVMD in Q1 2020 and held it in 2 quarters. The position peaked at $2.63M in Q1 2026. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Davidson Kempner Capital Management reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 27,075 Revolution Medicines shares in Q2 2026, an estimated $2.63M.
  • Davidson Kempner Capital Management first reported a position in Revolution Medicines in Q1 2020 and held it in 2 quarters.
  • Davidson Kempner Capital Management's Revolution Medicines position peaked at $2.63M in Q1 2026.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Davidson Kempner Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.